Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials

By afschroeder • November 29, 2025

Guttman-Yassky E, Kabashima K, Worm M, Luna PC, Hong HC, Chovatiya R, Bernstein JA, Kern JS, Ehst BD, Magnolo N, Herranz-Pinto P, Stein Gold L, Sofen H, Pink AE, Esfandiari E, Arai T, Yang Y, Shi R, Barragan C, Kricorian G, Schwartz-Sagi L, Bissonnette R. Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials. Lancet. 2025 Nov 25:S0140-6736(25)01865-3. doi: 10.1016/S0140-6736(25)01865-3. Epub ahead of print. PMID: 41314226.

Tags: Dermatology, Olive View DoM, Publications

US expert opinions on the treatment of bullous pemphigoid based on guidelines from the European Academy of Dermatology and Venereology

Kasperkiewicz M, Thapa M, Adotama P, Tomayko MM, Culton DA. US expert opinions on the treatment of bullous pemphigoid based on guidelines from the European[...]

Single-cell and spatial profiling reveal cDC2A-CXCL13+CD8+ T-epithelial cell crosstalk and cytotoxicity through TNFRSF9 in cutaneous and mucosal lichen planus

Jiang R, Bogle R, Xing X, Kirma J, Fox J, Harms PW, Do T, Billi AC, Kahlenberg JM, Modlin RL, Teles R, West J, Mangold[...]

Concordance Between Patient- and Physician-Reported Improvement With Dupilumab in Atopic Dermatitis

Conde G, Carmenate Y, Bello G, Armstrong AW. Concordance Between Patient- and Physician-Reported Improvement With Dupilumab in Atopic Dermatitis. J Dermatol. 2026 Mar 13. doi:[...]